Report on clinical and preclinical data presented at a mitochondrial medicine meeting evaluating a novel mitochondrial therapy for primary CoQ10 deficiency.
Key Takeaways
- No FDA-approved therapies exist for primary CoQ10 deficiency
- Mouse disease models showed BPM31510 increased CoQ levels in brain and kidney
- In four pediatric compassionate-use cases, BPM31510 was well tolerated and improved ataxia within four weeks